阿姆斯特丹男男性行为者甲型肝炎发病率、血清流行率及疫苗接种决策
研究利用1992-2017年监测数据估计阿姆斯特丹MSM急性甲肝发病率,并分析2006-2017年STI门诊MSM的甲肝血清流行率及疫苗接种选择。结果显示2016/17年发病率回升,血清流行率37%(95%CI=35-40%),免费接种时89%选择接种,付费时仅11%。
要点
- 阿姆斯特丹MSM甲肝血清流行率37%(95%CI=35-40%),随年龄增长而升高。
- 免费提供甲肝疫苗时89%的MSM选择接种,付费75欧元时仅11%(p<0.001)。
- 年轻MSM在需付费时接种意愿更低(p=0.010)。
核心结论
- 阿姆斯特丹MSM人群对甲肝新发疫情易感,强烈建议为MSM提供免费甲肝疫苗接种。
研究设计与样本
- 使用1992-2017年阿姆斯特丹MSM急性甲肝监测数据估计发病率和年龄分布。
- 利用2006-2017年STI门诊MSM数据(纳入全国HBV疫苗接种项目)分析甲肝血清流行率、阳性决定因素及接种选择。
- 甲肝疫苗接种在STI门诊分三个连续阶段:不提供、免费提供、收费75欧元。
- 采用逻辑回归分析决定因素。
主要发现
- 甲肝发病率在消失4年后于2016/17年上升,在约35岁MSM中达到高峰。
- STI门诊MSM甲肝血清流行率为37%(95%CI=35-40%),2006-2017年间保持稳定,随年龄增长而升高(p<0.001)。
- 多变量分析中甲肝血清阳性的决定因素包括:年龄较大(p<0.001)、来自甲肝流行国家(p<0.001)、HBV血清阳性(p=0.001)。
- 免费提供甲肝疫苗时MSM选择接种的比例为89%,付费时为11%(p<0.001)。
- 需付费时年轻MSM接种意愿更低(p=0.010)。
关键数值与推荐
- 甲肝血清流行率37%(95%CI=35-40%)。
- 免费 vs 付费接种选择率:89% vs 11%(p<0.001)。
- 免费 vs 收费75欧元时预计保护率:98% vs 46%。
临床怎么用
- 在STI门诊为MSM免费提供甲肝疫苗接种可大幅提高接种意愿和人群保护率。
- 应优先关注年轻MSM的接种障碍,尤其是付费要求下的低接种意愿。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several outbreaks of Hepatitis A virus (HAV) were recently documented among men who have sex with men (MSM) in Europe. We investigated the HAV incidence among MSM in Amsterdam, the Netherlands; and HAV seroprevalence and HAV vaccination decision among MSM visiting the Sexually Transmitted Infection (STI) clinic in Amsterdam. METHODS: Using surveillance data from 1992 to 2017 of MSM with acute HAV in Amsterdam, we estimated the incidence by calendar year and age. We explored HAV seroprevalence by calendar year and age, determinants for HAV seropositivity, and opting-in/out for HAV vaccination using data collected among MSM that visited the STI clinic between 2006 and 2017 and were included in a nationwide Hepatitis B virus (HBV) vaccination programme. Offering HAV vaccination at the STI clinic differed over three consecutive periods: not offered, offered for free, or offered for 75 euros. Logistic regression analyses were used to explore determinants. RESULTS: HAV incidence increased in 2016/17 after 4 years of absence and peaked in MSM around 35 years of age. Among MSM visiting the STI clinic, HAV seroprevalence was 37% (95%CI = 35-40%), which was constant over the period 2006-2017, and increased with age (p < 0.001). Determinants for HAV seropositivity in multivariable analysis were: older age (p < 0.001), originating from an HAV endemic country (p < 0.001), and being HBV seropositive (p = 0.001). MSM opted-in more frequently when HAV vaccination was offered for free versus paid (89% versus 11%, respectively; p < 0.001). Younger MSM were less inclined to vaccinate when payment was required (p = 0.010). Post-hoc analyses showed that 98% versus 46% of MSM visiting the Amsterdam STI clinic would be protected against HAV infection if HAV vaccination was offered for free or for 75 euros, respectively. CONCLUSIONS: The MSM population of Amsterdam is vulnerable to a new HAV outbreak. We strongly recommend that MSM have access to free hepatitis A vaccination.
引用
- Alberts CJ, Boyd A, Bruisten SM, et al. Hepatitis A incidence, seroprevalence, and vaccination decision among MSM in Amsterdam, the Netherlands. Vaccine. 2019. PMID: 30992222. doi:10.1016/j.vaccine.2019.03.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。